Get to know PDRN

PDRN(polydeoxyribonucleotide) was first extracted from salmon germ cells by Italian scientists, and was first discovered and studied by the Italian company Mastelli in 1952.

The commercialization of PDRN began in 2008, when Placentex, a brand of Mastelli, was launched and approved in Korea for the treatment of tissue repair and skin grafting wounds.

It was then that Mastelli Italia’s Placentex (Skin Booster) brand was launched and in the same year PDRN was approved in South Korea for the treatment of tissue repair and skin graft wounds.

PDRN has been extracted and purified from human placenta, red algae, ginseng, and sperm cells from salmon trout or salmon. The molecular weight of PDRN ranges from 50 to 1500 kDa, and consists of 50% double-stranded deoxyribonucleotides, which are linked by hydrogen bonds between base pairs to form a double helix structure.

The mechanism of action of PDRN is two fold: firstly, it provides raw material for cellular DNA synthesis through the “remedial pathway”; secondly, it acts as an agonist of adenosine receptor (A2A), which is involved in activation or inhibition of multiple pathways, regulating downstream products and thus exerting multiple pharmacological effects.

By activating the adenosine A2A receptor, PDRN inhibits inflammation and promotes cell growth and angiogenesis, thereby accelerating tissue regeneration and wound healing.

Thus PDRN is totally different from the dermal filler’s function. The main function of a dermal filler treatment is to conceal and improve visible signs of ageing and enhance deficient areas of the face. Whereas for PDRN injection, the aim is to leverage on its reparative benefits to treat skin damage.

Market Trends for PDRN

The global Polydeoxyribonucleotides (PDRN) market reached sales of $25.77 million in 2022 and is expected to reach $284.78 million in 2029, growing at a compound annual growth rate (CAGR) of 43.32% (2023-2029).

At the regional level, the Chinese market has been changing rapidly over the past few years, with a market size of $6.89 million in 2022, accounting for approximately 26.74% of the global market, and is expected to reach $96.46 million in 2029, when the global share will reach 33.87%.

ACMISAWA PDRN, Premium Skin Booster Manufacturer

As the pioneer on medical and biomedical industry, ACMISAWA’ aesthetic focus on the research and development on various skin boosters with the latest international standards and advanced technology, and strive to provide high-quality PDRN to worldwide distributors, aesthetic clinics.